Cargando…

Incidence, mechanism and prognostic value of activated AKT in pancreas cancer

When activated, the serine/threonine kinase AKT mediates an antiapoptotic signal implicated in chemoresistance of various cancers. The mechanism(s) of AKT activation are unknown, though overexpression of HER-2/neu has been implicated in breast cancer. Therefore, we determined the incidence of activa...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlieman, M G, Fahy, B N, Ramsamooj, R, Beckett, L, Bold, R J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376856/
https://www.ncbi.nlm.nih.gov/pubmed/14647146
http://dx.doi.org/10.1038/sj.bjc.6601396
_version_ 1782154745283084288
author Schlieman, M G
Fahy, B N
Ramsamooj, R
Beckett, L
Bold, R J
author_facet Schlieman, M G
Fahy, B N
Ramsamooj, R
Beckett, L
Bold, R J
author_sort Schlieman, M G
collection PubMed
description When activated, the serine/threonine kinase AKT mediates an antiapoptotic signal implicated in chemoresistance of various cancers. The mechanism(s) of AKT activation are unknown, though overexpression of HER-2/neu has been implicated in breast cancer. Therefore, we determined the incidence of activated AKT in human pancreatic cancer, whether HER-2/neu is involved in AKT activation, and if AKT activation is associated with biologic behaviour. HER-2/neu expression and AKT activation were examined in seven pancreatic cancer cell lines by Western blotting. The in vitro effect of HER-2/neu inhibition on AKT activation was similarly determined. Finally, 78 pancreatic cancer specimens were examined for AKT activation and HER-2/neu overexpression, and correlated with the clinical prognostic variable of histologic grade. HER-2/neu was overexpressed in two of seven cell lines; these two cell lines demonstrated the highest level of AKT activation. Inhibition of HER-2/neu reduced AKT activation in vitro. AKT was activated in 46 out of 78 (59%) of the pancreatic cancers; HER-2/neu overexpression correlated with AKT activation (P=0.015). Furthermore, AKT activation was correlated with higher histologic tumour grade (P=0.047). Thus, it is concluded that AKT is frequently activated in pancreatic cancer; this antiapoptotic signal may be mediated by HER-2/neu overexpression. AKT activation is associated with tumour grade, an important prognostic factor.
format Text
id pubmed-2376856
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23768562009-09-10 Incidence, mechanism and prognostic value of activated AKT in pancreas cancer Schlieman, M G Fahy, B N Ramsamooj, R Beckett, L Bold, R J Br J Cancer Molecular and Cellular Pathology When activated, the serine/threonine kinase AKT mediates an antiapoptotic signal implicated in chemoresistance of various cancers. The mechanism(s) of AKT activation are unknown, though overexpression of HER-2/neu has been implicated in breast cancer. Therefore, we determined the incidence of activated AKT in human pancreatic cancer, whether HER-2/neu is involved in AKT activation, and if AKT activation is associated with biologic behaviour. HER-2/neu expression and AKT activation were examined in seven pancreatic cancer cell lines by Western blotting. The in vitro effect of HER-2/neu inhibition on AKT activation was similarly determined. Finally, 78 pancreatic cancer specimens were examined for AKT activation and HER-2/neu overexpression, and correlated with the clinical prognostic variable of histologic grade. HER-2/neu was overexpressed in two of seven cell lines; these two cell lines demonstrated the highest level of AKT activation. Inhibition of HER-2/neu reduced AKT activation in vitro. AKT was activated in 46 out of 78 (59%) of the pancreatic cancers; HER-2/neu overexpression correlated with AKT activation (P=0.015). Furthermore, AKT activation was correlated with higher histologic tumour grade (P=0.047). Thus, it is concluded that AKT is frequently activated in pancreatic cancer; this antiapoptotic signal may be mediated by HER-2/neu overexpression. AKT activation is associated with tumour grade, an important prognostic factor. Nature Publishing Group 2003-12-01 2003-11-25 /pmc/articles/PMC2376856/ /pubmed/14647146 http://dx.doi.org/10.1038/sj.bjc.6601396 Text en Copyright © 2003 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Molecular and Cellular Pathology
Schlieman, M G
Fahy, B N
Ramsamooj, R
Beckett, L
Bold, R J
Incidence, mechanism and prognostic value of activated AKT in pancreas cancer
title Incidence, mechanism and prognostic value of activated AKT in pancreas cancer
title_full Incidence, mechanism and prognostic value of activated AKT in pancreas cancer
title_fullStr Incidence, mechanism and prognostic value of activated AKT in pancreas cancer
title_full_unstemmed Incidence, mechanism and prognostic value of activated AKT in pancreas cancer
title_short Incidence, mechanism and prognostic value of activated AKT in pancreas cancer
title_sort incidence, mechanism and prognostic value of activated akt in pancreas cancer
topic Molecular and Cellular Pathology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376856/
https://www.ncbi.nlm.nih.gov/pubmed/14647146
http://dx.doi.org/10.1038/sj.bjc.6601396
work_keys_str_mv AT schliemanmg incidencemechanismandprognosticvalueofactivatedaktinpancreascancer
AT fahybn incidencemechanismandprognosticvalueofactivatedaktinpancreascancer
AT ramsamoojr incidencemechanismandprognosticvalueofactivatedaktinpancreascancer
AT beckettl incidencemechanismandprognosticvalueofactivatedaktinpancreascancer
AT boldrj incidencemechanismandprognosticvalueofactivatedaktinpancreascancer